BTIG Research Cuts Abbott Laboratories (NYSE:ABT) Price Target to $131.00

Abbott Laboratories (NYSE:ABT) had its target price trimmed by BTIG Research from $140.00 to $131.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a buy rating on the healthcare product maker’s stock.

Several other equities research analysts also recently weighed in on ABT. Sanford C. Bernstein cut their price target on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. The Goldman Sachs Group decreased their price objective on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Argus lowered their target price on Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Barclays reduced their price target on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd. Finally, Citigroup decreased their price target on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a report on Wednesday, March 11th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $135.68.

Abbott Laboratories Stock Performance

ABT opened at $102.84 on Tuesday. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a 12-month low of $100.88 and a 12-month high of $139.06. The firm has a 50 day moving average of $109.57 and a two-hundred day moving average of $121.31. The firm has a market capitalization of $179.11 billion, a PE ratio of 27.65, a P/E/G ratio of 1.63 and a beta of 0.79.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same quarter in the prior year, the business earned $1.34 earnings per share. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Insider Buying and Selling

In other news, EVP Mary K. Moreland sold 613 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the transaction, the executive vice president directly owned 104,291 shares of the company’s stock, valued at $12,053,953.78. This represents a 0.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were acquired at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the transaction, the director directly owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. This represents a 0.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold a total of 3,055 shares of company stock worth $353,097 in the last ninety days. 0.46% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Abbott Laboratories

A number of large investors have recently added to or reduced their stakes in the stock. J. Derek Lewis & Associates Inc. purchased a new position in Abbott Laboratories in the 4th quarter valued at about $1,992,000. Purpose Unlimited Inc. purchased a new stake in Abbott Laboratories during the 4th quarter worth approximately $25,000. Stance Capital LLC raised its holdings in shares of Abbott Laboratories by 12.8% during the fourth quarter. Stance Capital LLC now owns 11,339 shares of the healthcare product maker’s stock valued at $1,421,000 after acquiring an additional 1,291 shares during the last quarter. Cornerstone Planning LLC purchased a new position in shares of Abbott Laboratories in the fourth quarter valued at approximately $2,858,000. Finally, Rockefeller Capital Management L.P. boosted its stake in shares of Abbott Laboratories by 27.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,377,659 shares of the healthcare product maker’s stock worth $172,607,000 after acquiring an additional 297,268 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott joined Whoop’s $575M Series G as a strategic investor, linking its diagnostics/device expertise to Whoop’s consumer wearable and insights platform — a move that could accelerate Abbott’s digital-health footprint and recurring-data opportunities. Abbott’s Whoop Investment Puts Digital Health Wearables On Shareholders’ Radar
• Positive Sentiment: Trade press confirms the Whoop deal and frames it as a strategic partnership to “empower people to take control of their health,” reinforcing investor interest in recurring-data and consumer channels. Abbott joins $575M funding round for wearable maker Whoop
• Neutral Sentiment: Several analyst pieces and screeners are revisiting ABT’s valuation and earnings setup (comparisons with GE HealthCare, “reasons to retain” commentary, trending-stock writeups). These note durable FreeStyle Libre growth and a Nutrition rebound but warn currency/macro headwinds — evidence that views are mixed rather than uniformly bullish. GEHC or ABT: Which Is the Better Value Stock Right Now?
• Positive Sentiment: At least one outlet upgraded Abbott’s investment case heading into Q1 earnings, highlighting the company’s diversified franchise and margin/growth outlook — a potential tailwind if Q1/guide reassure investors. Abbott: A Brighter Investment Case Heading Into Q1 Earnings (Rating Upgrade)
• Negative Sentiment: BTIG lowered expectations for ABT’s stock price, adding analyst pressure that could cap gains until management proves guidance/organic growth trajectory. BTIG Research Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price
• Negative Sentiment: Coverage noting that Abbott is ~26% below its 52-week high after a soft quarter underscores investor concern about near-term topline pressure despite long-term dividend credibility. This Dividend King Is Down 26%. When Will It Bounce Back?

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.